Geron Reports Strong RYTELO Revenue Growth but Faces Rising Costs
Event summary
- Geron reported $48 million in RYTELO net product revenue for Q4 2025, up 9% from Q3 2025.
- Full-year 2025 RYTELO revenue reached $184 million, with total operating expenses at $255 million.
- Geron ended 2025 with $401 million in cash and marketable securities, down from $502.9 million in 2024.
- The company implemented a workforce reduction in December 2025, cutting approximately one-third of its workforce.
- 2026 guidance projects RYTELO net product revenue between $220 million and $240 million.
The big picture
Geron's strong RYTELO revenue growth in 2025 positions it as a key player in the blood cancer treatment market. However, rising operating expenses and a significant workforce reduction highlight the challenges of balancing growth with financial discipline. The company's ability to execute its commercial strategy and navigate regulatory milestones will be critical in sustaining its market position.
What we're watching
- Commercial Execution
- Whether Geron can sustain the 9% quarterly demand growth for RYTELO in 2026.
- Cost Control
- The pace at which Geron can reduce operating expenses while investing in commercial growth.
- Regulatory Milestones
- The impact of interim analysis in relapsed/refractory myelofibrosis and real-world experience trials on RYTELO's market potential.
Related topics